Reply to comment
Acambis - Sanofi Pasteur
March 31, 2009 by Anonymous, 33 weeks 6 days ago
Comment id: 35744
Reply
About us
Science Blog was started in August 2002. It lives, breathes and eats press releases from research organizations around the globe. Most of what you read here are press releases from the outfits named in the stories themselves. Got a news story you think belongs here? Let's talk. The other half of the equation is blog posts from readers like you. So if you have an interest in science, please register and join others like you in an ongoing, vibrant dialog about what makes the world tick. Meantime, please take a minute to read our Privacy Policy and Site Disclaimer.Recommended
Andrew Sullivan Dan Sullivan Doug Arellanes Emmanuelle Richard Faith Sullivan Fred Bortz Heather Havrilesky Henry Copeland Kate Sullivan Ken Layne lagreenbean.com LAist.com Maggie Sullivan Matt Welch NewYorkology Opinion L.A. Ron Kaye Slashdot Steve Elzer & Family TheNewsroom.org Thor Garcia Tony Pierce Wonkette OlderThanks CNET for naming Science Blog one of your Blog 100!
Sanofi-Pasteur just gobbled up Acambis for $549mn. Last year Acambis announced that it had a promising vaccine that is good in men & women & could also help folks already afflicted with recurrent HSV-2. This looks like the most promising breakthrough on the horizon and they are apparently supposed to be filing an "investigational drug" application sometime in 2009 which would make it more accessible to the public.
Harvard is somehow involved with this Acambis vaccine and they have a huge research endowment. The competition is fierce out there which is good for anyone with or at risk for HSV 1 or 2. American women are really affected by HSV-2 - about 30% and that just stinks. They estimate that a vaccine will generate the winner $2bn a year in revenue - that's a big prize. With the Valtrex patent expiring in June 2009 you're bound to see some breakthroughs.